Evolution of Rifampicin (cas 13292-46-1) treatment for tuberculosis

Add time:07/17/2019    Source:sciencedirect.com

Rifampicin (cas 13292-46-1) was discovered in 1965 and remains one of the most important drugs in tuberculosis treatment that is valued for its sterilizing activity and ability to shorten treatment. Antimicrobial activity of rifampicin was initially proved in vitro; subsequently numerous in vivo studies showed the bactericidal properties and dose-dependent effect of rifampicin. Rifampicin was first during the late 1960s to treat patients suffering from chronic drug-resistant pulmonary TB. Decades later, rifampicin continues to be studied with particular emphasis on whether higher doses could shorten the duration of treatment without increasing relapse or having adverse effects. Lesion-specific drug penetration and pharmacokinetics of rifampicin are improving our understanding of effective concentration while potentially refining drug regimen designs. Another prospective aspect of high-dose rifampicin is its potential use in treating discrepant mutation thereby eliminating the need for MDR treatment. To date, several clinical trials have shown the safety, efficacy, and tolerability of high-dose rifampicin. Currently, high-dose rifampicin has been used successfully in a routine clinical setting for the treatment of high-risk patients. However, the WHO and other relevant policy makers have not committed to implementing a controlled rollout thereof. This review describes the course that rifampicin has travelled to the present-day exploration of high-dose rifampicin treatment.

We also recommend Trading Suppliers and Manufacturers of Rifampicin (cas 13292-46-1). Pls Click Website Link as below: cas 13292-46-1 suppliers

Prev:Induction and inhibition of hepatic drug metabolizing enzymes by rifampin
Next:The optimization of methadone dosing whilst treating with Rifampicin (cas 13292-46-1): A pharmacokinetic modeling study)